Structure-based engineering of immunomodulatory agents for the treatment of cancer
Abstract/Contents
- Abstract
- Immune-based therapies for cancer are powerful, lasting, and generally less toxic than most other cancer treatment paradigms. Consequently, the development of new immunotherapeutic agents and the study of the interplay between tumors and the immune system have emerged as central lines of research for this nascent field of medicine. Here, I describe my efforts to improve an existing cancer immunotherapy (Interleukin-2), to study an experimental immunotherapeutic agent (Interleukin-15), and to generate novel protein therapeutics against an emerging target of cancer immune evasion (CD47). These studies highlight a structure- and mechanism-based approach to protein engineering in the development of next-generation cancer immunotherapies.
Description
| Type of resource | text |
|---|---|
| Form | electronic; electronic resource; remote |
| Extent | 1 online resource. |
| Publication date | 2016 |
| Issuance | monographic |
| Language | English |
Creators/Contributors
| Associated with | Ring, Aaron Michael |
|---|---|
| Associated with | Stanford University, Department of Structural Biology. |
| Primary advisor | Garcia, K. Christopher |
| Thesis advisor | Garcia, K. Christopher |
| Thesis advisor | Kobilka, Brian K |
| Thesis advisor | Majeti, Ravindra, 1972- |
| Thesis advisor | Weissman, Irving L |
| Advisor | Kobilka, Brian K |
| Advisor | Majeti, Ravindra, 1972- |
| Advisor | Weissman, Irving L |
Subjects
| Genre | Theses |
|---|
Bibliographic information
| Statement of responsibility | Aaron Michael Ring. |
|---|---|
| Note | Submitted to the Department of Structural Biology. |
| Thesis | Thesis (Ph.D.)--Stanford University, 2016. |
| Location | electronic resource |
Access conditions
- Copyright
- © 2016 by Aaron Michael Ring
- License
- This work is licensed under a Creative Commons Attribution Non Commercial 3.0 Unported license (CC BY-NC).
Also listed in
Loading usage metrics...